This includes broadening its efforts to evaluate the potential for nitrosamines in drugs other than sartans and measures to address and prevent the impurities. For those who asked, Pepcid (famotidine) and Tagamet (cimetidine) are the same class of drug as Zantac (H2 blockers). This includes conducting its own tests and assessing whether the results seen in laboratory tests present a human health risk. Health Canada continues to gather and share information with other regulators, including the U.S. Food and Drug Administration and the European Medicines Agency, and with Canadian companies to better understand the issue and whether there may be a risk to Canadians. Health Canada recently provided an update on the This is different from a recall, since products that are being recalled can no longer be sold. Should any additional recalls be necessary, Health Canada will update the table below and inform Canadians. Please refer to the Affected Products table below for detailed information on the recalled lots. Should any additional recalls be necessary, Health Canada will update the table below and inform Canadians.The request to stop distribution means that the existing stock of ranitidine products currently available in pharmacies or at retail stores may continue to be sold. Companies have agreed with Health Canada's precautionary request to stop distributing all ranitidine drugs in Canada. The Department will take action if a risk to Canadians is identified, and will continue to inform the public of new safety information. Prescription ranitidine drugs are used to reduce stomach acid for the treatment and prevention of various conditions, such as heartburn, ulcers of the stomach and intestines, and gastroesophageal reflux disease (commonly known as GERD). Should any additional recalls be necessary, Health Canada will update the table below and inform Canadians. On September 24th 2019, the FDA announced a voluntary recall of 14 lots of prescription ranitidine capsules from manufacturer Sandoz, Inc. FDA News Release. C. APO-Ranitidine Tablet 150mg. One company, Sandoz Canada, is recalling its oral prescription products in Canada and other countries after testing identified levels of NDMA above what is considered acceptable if the drug were to be taken over a lifetime. Sandoz has voluntarily recalled its 150mg and 300 mg ranitidine tablets. Ranitidine is available in Canada over-the-counter (for example, under the brand name Zantac and as generics) and by prescription (as generics). UPDATE: Pharmascience Inc. recalls one lot of PMS-Ranitidine as a precaution. UPDATE: August 31, 2020 – Pharmascience Inc. recalls one lot of PMS-Ranitidine as a precaution. Over-the-counter ranitidine is approved to prevent and relieve heartburn associated with acid indigestion and sour stomach. Last updated: 2019-09-26. B. Equate Acid Reducer. Consumers and patients who are taking a ranitidine drug. Distributor … We are all exposed to low levels of NDMA in some foods (such as meats, dairy products and vegetables) and in drinking water. Should any additional recalls be necessary, Health Canada will update the table below and inform Canadians. As of this writing, the FDA has NOT issued a blanket recall of all ranitidine products. Please refer to the Affected Products table below for detailed information on the recalled lots. Should any additional recalls be deemed necessary, Health Canada will update the table below and inform Canadians. Should any additional recalls be necessary, Health Canada will update the table below and inform Canadians. FDA Requests Removal of All Ranitidine Products (Zantac) from the Market FDA Advises Consumers, Patients and Health Care … Dominion Pharmacal, Laboratoire Riva Inc., Pharmascience Inc. and Vita Health Inc. are recalling all lots of their prescription and over-the-counter ranitidine products from the Canadian market as a precautionary measure. Health Canada continues to work closely with international regulatory partners to address the issue. The Department will take action if a risk to Canadians is identified, and will continue to inform the public of new safety information. Pharmascience Inc. is recalling one lot of prescription PMS-Ranitidine (150 mg strength tablet) as a precaution after tests found NDMA, a nitrosamine impurity, at close to the accepted level.